Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Alpha-1 Antitrypsin Deficiency Disease Treatment Market

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Share

Report ID: GMI11707
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Share

The market is characterized by a highly competitive landscape, marked by rapid innovation and technological progress. Prominent pharmaceutical companies hold a significant share of the market, driven by their extensive portfolios of diagnostic tests and advanced treatment options, including a variety of medications and emerging therapeutic modalities. Strategic initiatives, such as mergers, acquisitions, and collaborations, further strengthen the market positions of key players, allowing them to expand their product offerings and access new markets.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Companies

The company profile section includes both companies that have commercial drugs available in the market as well as those that are onto clinical phase development. Prominent players operating in the alpha-1 antitrypsin deficiency disease treatment industry include:

Arrowhead Pharmaceuticals, Inc.
CHIESI Farmaceutici S.p.A.
CSL Behring
Epicrispr Biotechnologies, Inc.
GlaxoSmithKline plc
Grifols S.A.
Intellia Therapeutics, Inc.
Kamada Pharmaceuticals
Mayo Foundation for Medical Education and Research
National Jewish Health
Shire Plc (Takeda Pharmaceutical Company Limited)
The General Hospital Corporation
The Johns Hopkins Hospital

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market was valued at USD 2.6 billion in 2023 and is projected to grow at a 10.1% CAGR from 2024 to 2032. This growth is driven by the rising incidence of related respiratory and liver diseases, increased awareness and screening programs, advancements in diagnostic technologies, and the development of effective treatment options.

The adult segment dominated the market with USD 2.3 billion in 2023, driven by increased disease awareness and advancements in therapeutic options.

The North American market is expected to grow at a 9.8% CAGR, reaching USD 2.9 billion by 2032. This growth is driven by significant advancements in therapeutic interventions and a high prevalence of AATD, particularly among the growing geriatric population.

Key players include Arrowhead Pharmaceuticals, Inc., CHIESI Farmaceutici S.p.A., CSL Behring, Epicrispr Biotechnologies, Inc., GlaxoSmithKline plc, Grifols S.A., Intellia Therapeutics, Inc., and Kamada Pharmaceuticals.